Fiera Capital Corp Has $63.52 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Fiera Capital Corp lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 23.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 125,735 shares of the company's stock after selling 38,574 shares during the period. Fiera Capital Corp owned 0.15% of IDEXX Laboratories worth $63,524,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Csenge Advisory Group grew its stake in shares of IDEXX Laboratories by 21.4% during the first quarter. Csenge Advisory Group now owns 943 shares of the company's stock worth $509,000 after purchasing an additional 166 shares during the period. Empirical Finance LLC increased its stake in shares of IDEXX Laboratories by 3.4% in the 1st quarter. Empirical Finance LLC now owns 3,021 shares of the company's stock valued at $1,631,000 after acquiring an additional 100 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its position in shares of IDEXX Laboratories by 42.8% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 20,835 shares of the company's stock valued at $11,249,000 after acquiring an additional 6,249 shares during the period. Empowered Funds LLC grew its holdings in IDEXX Laboratories by 28.0% during the first quarter. Empowered Funds LLC now owns 1,039 shares of the company's stock valued at $561,000 after purchasing an additional 227 shares during the period. Finally, SG Americas Securities LLC increased its stake in IDEXX Laboratories by 11.4% in the first quarter. SG Americas Securities LLC now owns 21,420 shares of the company's stock valued at $11,565,000 after purchasing an additional 2,196 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. JPMorgan Chase & Co. cut their target price on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research note on Friday, October 11th. Piper Sandler reaffirmed a "neutral" rating and issued a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday. BTIG Research started coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They set a "buy" rating and a $580.00 price target on the stock. Barclays reduced their target price on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a report on Monday. Finally, Stifel Nicolaus lowered their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a research report on Thursday, October 10th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $552.38.

IDEXX Laboratories Stock Up 0.1 %

Shares of IDEXX Laboratories stock traded up $0.28 during trading on Friday, reaching $433.28. 655,723 shares of the company traded hands, compared to its average volume of 498,605. The firm has a market capitalization of $35.48 billion, a PE ratio of 41.78, a P/E/G ratio of 3.61 and a beta of 1.36. IDEXX Laboratories, Inc. has a 1-year low of $404.74 and a 1-year high of $583.39. The company has a 50 day moving average price of $472.83 and a 200-day moving average price of $485.19. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company had revenue of $975.50 million for the quarter, compared to analysts' expectations of $980.32 million. During the same quarter in the prior year, the firm earned $2.53 EPS. The business's revenue was up 6.6% on a year-over-year basis. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 10.45 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.